Mixed Connective Tissue Disease

This is a rare autoimmune disease that affects many parts of the body. It can cause symptoms similar to several other conditions, like lupus, scleroderma, and polymyositis. People with this disease often have trouble with their blood vessels (Raynaud's), muscles, and skin. It's diagnosed based on specific blood tests and skin biopsies.

Condition

What people with Mixed Connective Tissue Disease report

Every report comes from a Lived member, sent anonymously.

Have you tried Hydroxychloroquine for Mixed Connective Tissue Disease?

NameHow it went

About Mixed Connective Tissue Disease

What It Is

Mixed connective tissue disease (MCTD) is an uncommon autoimmune condition in which the immune system causes inflammation in several parts of the body at once. Its defining feature is an overlap: a person has some features of lupus, scleroderma, polymyositis (an inflammatory muscle disease) and rheumatoid arthritis, together with a specific antibody in the blood called anti-RNP, which targets ribonucleoprotein (RNP), a normal component inside the body's cells. That antibody is what separates MCTD from other overlap conditions. Raynaud's phenomenon, in which fingers or toes turn white or blue and become painfully cold in response to cold or stress, affects more than 90% of people with MCTD and is often the first sign. Puffy, swollen hands, joint pain and fatigue are common early on. Others may develop lupus-like rashes, tightening of the skin on the fingers, muscle weakness in the hips and shoulders, or trouble swallowing and heartburn. MCTD matters because it can also reach the lungs and heart, sometimes years after the first symptoms. Despite the similar name, it is not related to inherited connective tissue disorders such as Ehlers-Danlos or Marfan syndrome, which involve the structure of the tissue rather than the immune system.

Causes & Risk Factors

MCTD is caused by autoimmunity: the immune system makes anti-RNP antibodies against a normal part of the body's own cells. The anti-RNP response appears to drive some of the damage as well as define the disease. Why it starts is not fully understood. Genes that shape how the immune system responds play a part, and MCTD is strongly linked to particular immune-system gene types (HLA types). Earlier infections, including some viral infections, may contribute in some people, but no single trigger has been shown to cause the disease, and nothing a person did is known to bring it on. MCTD can begin at any age from childhood to older adulthood, with an average onset in the late 30s. About three in four people affected are women.

How It's Diagnosed

No single test diagnoses MCTD. A rheumatologist puts together the symptom pattern, a physical examination and blood tests. The key blood finding is a high level of anti-RNP antibodies. These antibodies are almost always present in MCTD, but they also appear in other conditions such as lupus, so a positive result only counts alongside the typical clinical features, especially Raynaud's phenomenon, puffy fingers or swollen hands. There is no single agreed checklist, and doctors may use different sets of criteria. Because MCTD sits between better-known diseases, doctors also consider whether the picture fits lupus, scleroderma, myositis or rheumatoid arthritis instead, and the label can be revisited as the condition develops. Once MCTD is diagnosed, the assessment extends to organs that can be affected without obvious symptoms at first. Lung function testing is a routine part of this, and it is usually repeated over time to catch lung disease that appears later.

Treatment Options

There is no treatment designed specifically for MCTD, and no randomized trials have tested treatments in MCTD alone because the condition is rare. Doctors instead treat each problem according to which organs are involved, drawing on what works in lupus, scleroderma and myositis. Many people need nothing more than symptom control; others need stronger treatment for a particular organ. Joint pain and inflammation are often treated with nonsteroidal anti-inflammatory drugs (NSAIDs) or hydroxychloroquine, an antimalarial medicine widely used in lupus. Short or low-dose courses of corticosteroids such as prednisone can calm flares quickly, but long-term use brings significant side effects. High doses are used cautiously in MCTD because they make a rare but serious kidney complication called scleroderma renal crisis more likely. When arthritis persists, methotrexate or a similar disease-modifying drug may be added. Raynaud's phenomenon is managed by keeping the whole body warm, avoiding smoking and caffeine, and, if attacks are frequent, medicines that relax blood vessels, such as calcium channel blockers. Reflux and swallowing problems are treated with acid-reducing medicines and practical steps such as raising the head of the bed. Lung involvement changes the plan. Interstitial lung disease (inflammation and scarring of lung tissue) is usually treated with corticosteroids plus an immune-suppressing medicine such as mycophenolate, cyclophosphamide or rituximab, and an antifibrotic drug, nintedanib, may slow worsening when scarring keeps progressing. Pulmonary hypertension (high blood pressure in the arteries of the lungs) is treated with medicines that widen those arteries, such as sildenafil (sold for this purpose as Revatio). Some of these medicines, including methotrexate, mycophenolate and cyclophosphamide, can harm a developing baby, so anyone who could become pregnant should discuss pregnancy plans and contraception with the rheumatologist before starting them. Care often involves a team: a rheumatologist alongside lung, heart, kidney or digestive specialists and physical or occupational therapists as needed.

What to Expect

MCTD is usually long-lasting, but its course varies widely. Disease activity often eases over the years, and MCTD generally runs a milder course overall than lupus or scleroderma, although lung involvement can be serious. Lasting remission is uncommon, though many people have periods of low activity. After many years with the disease, a minority of people develop a pattern that more clearly fits another disease, such as lupus or scleroderma. Day to day, the main burdens are often cold-triggered Raynaud's attacks, joint pain, fatigue and reflux, which most people manage with treatment and routines such as dressing warmly and pacing activity. The outlook depends largely on the lungs. Pulmonary hypertension affects roughly one in eight people with MCTD and is the leading cause of death from the disease, and lung scarring is also common. Because both can develop quietly and early detection improves outcomes, regular follow-up with a rheumatologist, including repeated lung function tests and other checks the team recommends, continues even when someone feels well.

When to Seek Help

Arrange an evaluation if fingers or toes regularly turn white or blue in the cold and this comes with swollen fingers, joint pain or unexplained fatigue, since that combination can point to an autoimmune condition. If you have MCTD, contact your care team promptly about new or worsening breathlessness, especially with activity; chest pain when breathing; dizziness or fainting during exertion; or new swelling in the ankles or legs, since these can be early signs of lung or heart involvement. Also report new muscle weakness or worsening trouble swallowing.

Questions to Ask Your Doctor

  1. 1.Which features of lupus, scleroderma or myositis do I have, and which organs do we need to watch most closely?
  2. 2.How often should I have lung function tests or other heart and lung checks, even when I feel well?
  3. 3.What does each treatment you are suggesting aim to control, and what side effects or monitoring come with it?
  4. 4.Could my diagnosis change over time to lupus or scleroderma, and how would that affect my care?
  5. 5.Which changes in my breathing, swallowing or muscle strength should prompt me to call you rather than wait for my next appointment?

Last reviewed • Oct 2026

Educational content, not medical advice.